1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Re-Focused Kiadis Preps Trials With Natural Killer Cells

Revamped Biotech Trialling NK-cells In AML and HSCT

 
• By Sten Stovall

Kiadis Pharma’s CEO says its processed natural kill cell therapies can improve hematopoietic stem cell transplants and also treat resurgent leukemia.

Cancer_Cells
Kiadis is researching NK cells for their therapeutic potential • Source: Shutterstock

Restructured and refocused Dutch cell therapy specialist Kiadis Pharma Netherlands BV has received the regulatory go-ahead from who from the US Food and Drug Administration (FDA) to conduct multiple trials using its proprietary natural killer (NK) cells, with different investigational therapies set to start in two indications this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.